Monitor resp function during recovery; provide adequate ventilation if neuromuscular blockade reoccurs following extubation. Carefully monitor coagulation parameters in patients w/ known coagulopathies & in those using anticoagulants who received sugammadex 16 mg/kg dose. May increase risk of recurrence of neuromuscular blockade after initial reversal when used at lower than recommended doses. Onset of a depolarizing neuromuscular blocker might be slower. May require mechanical ventilation & re-administration of sugammadex in case neuromuscular blockade recurrence is observed. Potential interactions (eg, capturing & displacement). Occasionally, signs of light anesth (eg, movement, coughing, grimacing & tracheal tube suckling) were noted when neuromuscular blockade was reversed intentionally in the middle of anesth; if anesth is continued, additional doses of anesth &/or opioid may be given. Closely monitor patients for hemodynamic changes during & after reversal of neuromuscular blockade. Administer anti-cholinergics (eg, atropine) if clinically significant bradycardia is observed. Use in ICU. Not to be used to reverse block induced by nonsteroidal neuromuscular blockers (eg, succinylcholine or benzylisoquinolinium compd); steroidal neuromuscular blockers other than rocuronium or vecuronium. Delayed recovery time in CV disease, elderly or edematous state. Patients on a controlled Na diet. Not recommended in patients w/ severe renal impairment (including those requiring dialysis). Severe hepatic impairment. Pregnancy & lactation. Not recommended in term newborn infant & infant.
Sign Out
